All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1800+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Akeso's penpulimab (anti-PD-1) approved by Chinese NMPA for first-line treatment of recurrent or metastatic nasopharyngeal cancer with chemotherapy
Monoclonal antibody, nasopharyngeal cancer - Read more

AstraZeneca's Imfinzi (PD-L1 inhibitor) lands EC approval for limited-stage small-cell lung cancer after platinum-based chemoradiation therapy
Monoclonal antibody, lung cancer - Read more

PRESENTED BY DRUGBANK
Introducing the Next Evolution in Drug Discovery Intelligence

In the fast-paced world of pharmaceutical research and drug development, clarity and efficiency are everything. Yet, too often, researchers are left grappling with fragmented data sources, manual workflows, and missed opportunities.

That’s why we’re thrilled to introduce the next evolution of DrugBank.

Built on our trusted knowledge base, DrugBank consolidates fragmented drug intelligence into an intuitive AI-powered platform designed for biotech professionals to uncover insights, streamline decision-making, and accelerate drug discovery.

Be among the first to access the Future of Drug Discovery. Request Early Access Now.

⬇️ More Good News ⬇️

THE GOOD
Business Development

AstraZeneca in-licenses Alteogen's ALT-B4 technology to develop subcutaneous formulations of oncology drugs
Drug delivery, drug formulation, cancer - Read more

THE GOOD
Clinical Trials

Orca Bio touts positive Ph3 data for their Orca-T cell therapy in reducing GvHD complications in stem cell transplants
Cell therapy, graft versus host disease (GvHD), T cell therapy, allogeneic cell therapy - Read more

AstraZeneca showcases positive Ph1/2a data for puxitatug samrotecan (targeting B7-H4) in endometrial cancer
Antibody-drug conjugate (ADC), endometrial cancer - Read more [Paywall]

Avidity Bioscience's delpacibart zotadirsen (targeting TfR1) shows 25% dystrophin restoration in Ph1/2 trial for Duchenne muscular dystrophy
Antibody-oligonucleotide conjugate, Duchenne muscular dystrophy (DMD) - Read more

Zentalis's azenosertib (WEE1 inhibitor) shows 34.9% response rate in Ph2 trial for Cyclin E1+ platinum-resistant ovarian cancer patients
Small molecule, ovarian cancer - Read more

Sutro's luveltamab tazevibulin shows promising results targeting Folate Receptor-α in platinum resistant ovarian cancer patients in REFRαME-O1 trial with optimized dosing.
Antibody-drug conjugate (ADC), ovarian cancer - Read more

AstraZeneca/Alexion's eneboparatide (PTH receptor 1 agonist) met primary endpoint in Ph3 trial for chronic hypoparathyroidism, normalizing serum calcium.
Peptide, hypoparathyroidism - Read more

Scholar Rock's apitegromab targeting (targeting myostatin proforms) shows efficacy in Ph3 trial for patients with SMA receiving SMN-targeted treatments
Monoclonal antibody, spinal muscular atrophy (SMA) - Read more

Dyne Therapeutics' DYNE-251 (targeting TfR1) shows sustained functional improvement in patients with DMD in Ph1/2 trial
Antisense oligonucleotide, Duchenne muscular dystrophy (DMD) - Read more

Argent BioPharma reports positive Ph2b results for CimetrA, an anti-inflammatory treatment showing faster recovery in COVID-19 patients
Small molecule, inflammatory disease - Read more

Vertanical's cannabis extract VER-01 delivers Ph3 win in reducing chronic back pain without psychotropic effects
Small molecule, cannabinoid, pain, non-opioid pain - Read more (Press release in German)

vTv Therapeutics' cadisegliatin (liver-selective glucokinase activator) resumes Ph3 trial for type 1 diabetes as FDA lifts clinical hold
Small molecule, type 1 diabetes, clinical hold - Read more

THE GOOD
Company Incubation

Circular Genomics relocates to Eli Lilly’s Gateway Labs innovation hub in San Diego, California
Diagnostics, disease screening, Alzheimer's disease, biomarker, circular RNA biomarker - Read more

THE GOOD
Fundraises

Pillar VC raises $175M Fund IV to invest in scientific breakthroughs across AI, biology, and healthcare
Venture capital, life science investment, biotech Investing, AI - Read more

Curevo $110M Series B, clinical-stage biotech accelerating vaccine trials for shingles prevention
Vaccine, shingles, vaccine access - Read more

Maxion Therapeutics $72M Series A, developing antibody-based KnotBody drugs for ion channel and GPCR diseases
Antibody, inflammatory disease - Read more

Latigo Biotherapeutics $150M Series B, biotechnology company developing non-opioid pain medicines targeting source of pain
Small molecule, pain, non-opioid pain - Read more

Laplace Interventional $22M Series C, developing minimally invasive prosthetic valve for Tricuspid Regurgitation
Medical device, Tricuspid Regurgitation - Read more

Chance Pharma raised undisclosed funding to advance clinical trials for respiratory disease treatments
Small molecule, inhaled therapy, central nervous system (CNS) disorder, fibrosis-driven disease - Read more

THE GOOD
Marketing

Cell therapy CDMO BioCentriq rebrands as Made Scientific
Rebrand, cell therapy manufacturing, CDMO - Read more

UK pharma professional group welcomes back Novo Nordisk after two-year suspension for breaching code of practice regarding Saxenda promotion
Drug marketing, drug marketing violations, GLP-1, obesity - Read more

THE GOOD
Mergers & Acquisition

AstraZeneca bets big on cell therapies potential in-vivo future, snapping up EsoBiotec for up to $1B
Cell therapy, allogeneic cell therapy, CAR-T, multiple myeloma, cancer, autoimmune disease, solid tumor, in-vivo cell therapy - Read more

Taiho Pharmaceutical acquires ADC partner Araris Biotech for $400M upfront, $740M in milestones, gaining oncology expertise and pipeline
Antibody-drug conjugate (ADC), cancer, solid tumor, B cell lymphoma - Read more

iOncologi acquires TargImmune Therapeutics to advance RNA-based immunotherapies for solid tumors
dsRNA, RNA, cancer, solid tumor - Read more

THE GOOD
Partnerships

OPKO Health, Entera Bio partner on first oral GLP-1/glucagon dual agonist with shared ownership and development costs
GLP-1, obesity, clinical development, drug development - Read more

Avance Clinical signs clinical trial partnerships with four “premier” Taiwanese clinical sites
CRO (Contract Research Organization) - Read more

Fortress Biotech, Partex partnering to use AI platform for identifying biopharmaceutical assets for acquisition
Drug discovery, AI, small molecule - Read more

American Cancer Society, Layer Health partnering to accelerate cancer research using AI for patient data extraction
Research partnership, AI - Read more

THE GOOD
Politics & Policy

Drug companies agree to participate in Medicare's second round of price negotiations under Trump administration
Inflation Reduction Act, drug pricing, Centers for Medicare and Medicaid Services (CMS) - Read more

THE GOOD
Regulatory

FDA lifts REMS requirement for Idorsia's hypertension drug TRYVIO, simplifying access for patients and healthcare providers
Small molecule, hypertension, risk evaluation and mitigation strategy (REMS) - Read more

THE GOOD
Research

Celex Oncology develops treatment targeting sodium overload in tumor cells to control metastatic cancer
Bioelectricity, cancer - Read more

PRESENTED BY YOU?
Get the attention of 1800+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

Though Incyte's povorcitinib (JAK1 inhibitor) met Ph3 trial goals in hidradenitis suppurativa, these were below their Ph3 results and failed to meet investor expectations
Small molecule, hidradenitis suppurativa - Read more

THE BAD
Company Shutdown

Boston biotech HC Bioscience, which aimed to develop versatile tRNA drugs, has closed operations according to Endpoints
tRNA - Read more [Paywall]

THE BAD
Earnings & Finances

WuXi AppTec's US revenue growth fell to 7.7% amid Biosecure Act concerns, after previously growing 42% in 2023
CDMO, BIOSECURE Act - Read more [Paywall]

THE BAD
IPOs

Stada delays IPO until September due to market volatility, postponing planned $10.9 billion valuation
Monoclonal antibody, biosimilar, delayed IPO - Read more

THE BAD
Layoffs

Apriori Bio cuts 15 jobs as it shifts from platform building to pipeline development for clinical advancement
Vaccine, infectious disease, viral infection, AI - Read more

Merck & Co. plans 163 layoffs at Pennsylvania plant, with phased cuts from May through 2026 as site shuts down
Big pharma layoffs, antibiotics manufacturing - Read more

THE BAD
Politics & Policy

Trump administration defends HHS' rejection of drugmakers' 340B rebate models but hints at future reconsideration
US Department of Health & Human Services (HHS), 340B Drug Pricing Program - Read more [Paywall]

THE UGLY
Politics & Policy

NIH cancels 30-year diabetes study funding, allegedly amid Trump administration's actions against Columbia University
National Institute of Health (NIH), diabetes, chronic disease, federal research funding - Read more [Paywall]

THE UGLY
Public Health

WHO warns US funding cuts threaten global health progress, urges Trump to reconsider withdrawal
World Health Organization (WHO), infectious disease - Read more [Paywall]

THE UGLY
Shortages

FDA warns of hemodialysis tubing shortage through fall 2025; urges providers to conserve supplies while seeking alternatives
Dialysis, dialysis tubing - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here